GSK Expands its License Agreement with Zymework to Develop and Commercialize Bi-Specific Antibodies
Shots:
- Zymework to receive preclinical- development & commercial milestone payments and royalties on WW sales. GSK to get an option to develop and commercialize bi-specific candidates for multiple indications including infectious diseases utilizing Zymeworks’ heavy-light chain pairing technology of Azymetric platform
- In 2016- the companies collaborated to develop & commercialize up to six bispecific antibodies utilizing Zymeworks’s Azymetric platform
- Zymeworks’s Azymetric platform allows the transformation of monospecific Ab to bispecific Ab- enabling it to bind with two different targets- thus reducing toxicities and drug resistance
Ref: Business Wire | Image: GSK
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com